Healthequity (2HE) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2HE Analyst Ratings

Strong Buy

9 Buy

0 Hold

1 Sell

Based on 10 analysts giving stock ratings to

Healthequity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2HE Stock 12 Month Forecast

Average Price Target

€97.79

▲(16.42% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Healthequity in the last 3 months. The average price target is €97.79 with a high forecast of €107.23 and a low forecast of €75.49. The average price target represents a 16.42% change from the last price of €84.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"62":"€62","85":"€85","108":"€108","73.5":"€73.5","96.5":"€96.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107.2261875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€107.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.790283,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€97.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.487236,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€75.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[62,73.5,85,96.5,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.5,89.01739903846153,90.53479807692308,92.05219711538462,93.56959615384615,95.0869951923077,96.60439423076923,98.12179326923076,99.6391923076923,101.15659134615385,102.67399038461538,104.19138942307691,105.70878846153846,{"y":107.2261875,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.5,88.29156023076924,89.08312046153846,89.87468069230769,90.66624092307693,91.45780115384615,92.24936138461538,93.04092161538462,93.83248184615385,94.62404207692308,95.41560230769231,96.20716253846155,96.99872276923077,{"y":97.790283,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.5,86.57594123076923,85.65188246153846,84.7278236923077,83.80376492307693,82.87970615384616,81.95564738461539,81.0315886153846,80.10752984615384,79.18347107692307,78.2594123076923,77.33535353846153,76.41129476923076,{"y":75.487236,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€107.23

Average Price Target€97.79

Lowest Price Target€75.49

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Allen Lutz

Bank of America Securities

€107.23

Buy

27.65%

Upside

Reiterated

08/27/26

Alexander Paris

Barrington

€94.36

Buy

12.33%

Upside

Reiterated

08/24/26

Barrington Remains a Buy on Healthequity (HQY)

Stan Berenshteyn

Wells Fargo

€107.23

Buy

27.65%

Upside

Reiterated

08/24/26

Analysts Conflicted on These Healthcare Names: Natera (NASDAQ: NTRA), Healthequity (NASDAQ: HQY) and CSPC Pharmaceutical Group (Other OTC: CHJTF)

Scott Schoenhaus

KeyBanc

€107.23

Buy

27.65%

Upside

Reiterated

08/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NYSE: NVST), Healthequity (NASDAQ: HQY) and Insight Molecular Diagnostics (NASDAQ: IMDX)

David Larsen

BTIG

€94.36→€98.65

Buy

17.44%

Upside

Reiterated

07/24/26

Healthequity (HQY) Receives a Buy from BTIG

Ryan Halsted

RBC Capital

€92.64

Buy

10.29%

Upside

Reiterated

07/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)

Peter Warendorf

Barclays

€94.36

Buy

12.33%

Upside

Assigned

07/01/26

Healthequity (HQY) Gets a Buy from Barclays

Alexei Gogolev

J.P. Morgan

€105.51

Buy

25.61%

Upside

Reiterated

06/25/26

J.P. Morgan Remains a Buy on Healthequity (HQY)

Constantine Davides

Citizens JMP

€94.36→€95.22

Buy

13.35%

Upside

Reiterated

06/01/26

HealthEquity price target raised to $111 from $110 at CitizensHealthEquity price target raised to $111 from $110 at Citizens

David Roman

Goldman Sachs

€75.49

Sell

-10.13%

Downside

Reiterated

05/29/26

David Roman Reiterates Sell on HealthEquity as Elevated Expectations and Valuation Skew Risk‑Reward to the Downside

Sean Dodge

BMO Capital

€72.91→€90.07

Buy

7.23%

Upside

Upgraded

04/09/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN) and Healthequity (NASDAQ: HQY)

George Hill

Deutsche Bank

€102.94→€109.8

Buy

30.71%

Upside

Reiterated

03/19/26

HealthEquity price target raised to $128 from $120 at Deutsche BankHealthEquity price target raised to $128 from $120 at Deutsche Bank

Brian Tanquilut

Jefferies

€102.94→€92.64

Buy

10.29%

Upside

Reiterated

02/19/26

HealthEquity price target lowered to $108 from $120 at JefferiesHealthEquity price target lowered to $108 from $120 at Jefferies

Gregory Peters

Raymond James

€102.94→€85.78

Buy

2.12%

Upside

Reiterated

02/17/26

HealthEquity price target lowered to $100 from $120 at Raymond JamesHealthEquity price target lowered to $100 from $120 at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Allen Lutz

Bank of America Securities

€107.23

Buy

27.65%

Upside

Reiterated

08/27/26

Alexander Paris

Barrington

€94.36

Buy

12.33%

Upside

Reiterated

08/24/26

Barrington Remains a Buy on Healthequity (HQY)

Stan Berenshteyn

Wells Fargo

€107.23

Buy

27.65%

Upside

Reiterated

08/24/26

Analysts Conflicted on These Healthcare Names: Natera (NASDAQ: NTRA), Healthequity (NASDAQ: HQY) and CSPC Pharmaceutical Group (Other OTC: CHJTF)

Scott Schoenhaus

KeyBanc

€107.23

Buy

27.65%

Upside

Reiterated

08/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NYSE: NVST), Healthequity (NASDAQ: HQY) and Insight Molecular Diagnostics (NASDAQ: IMDX)

David Larsen

BTIG

€94.36→€98.65

Buy

17.44%

Upside

Reiterated

07/24/26

Healthequity (HQY) Receives a Buy from BTIG

Ryan Halsted

RBC Capital

€92.64

Buy

10.29%

Upside

Reiterated

07/08/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)

Peter Warendorf

Barclays

€94.36

Buy

12.33%

Upside

Assigned

07/01/26

Healthequity (HQY) Gets a Buy from Barclays

Alexei Gogolev

J.P. Morgan

€105.51

Buy

25.61%

Upside

Reiterated

06/25/26

J.P. Morgan Remains a Buy on Healthequity (HQY)

Constantine Davides

Citizens JMP

€94.36→€95.22

Buy

13.35%

Upside

Reiterated

06/01/26

HealthEquity price target raised to $111 from $110 at CitizensHealthEquity price target raised to $111 from $110 at Citizens

David Roman

Goldman Sachs

€75.49

Sell

-10.13%

Downside

Reiterated

05/29/26

David Roman Reiterates Sell on HealthEquity as Elevated Expectations and Valuation Skew Risk‑Reward to the Downside

Sean Dodge

BMO Capital

€72.91→€90.07

Buy

7.23%

Upside

Upgraded

04/09/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN) and Healthequity (NASDAQ: HQY)

George Hill

Deutsche Bank

€102.94→€109.8

Buy

30.71%

Upside

Reiterated

03/19/26

HealthEquity price target raised to $128 from $120 at Deutsche BankHealthEquity price target raised to $128 from $120 at Deutsche Bank

Brian Tanquilut

Jefferies

€102.94→€92.64

Buy

10.29%

Upside

Reiterated

02/19/26

HealthEquity price target lowered to $108 from $120 at JefferiesHealthEquity price target lowered to $108 from $120 at Jefferies

Gregory Peters

Raymond James

€102.94→€85.78

Buy

2.12%

Upside

Reiterated

02/17/26

HealthEquity price target lowered to $100 from $120 at Raymond JamesHealthEquity price target lowered to $100 from $120 at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Healthequity

3 Months

David LarsenBTIG

Success Rate

15/21 ratings generated profit

Average Return

+5.55%

Copying David Larsen's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +5.55% per trade.

1 Year

Alexander ParisBarrington

Success Rate

19/24 ratings generated profit

Average Return

+13.94%

Copying Alexander Paris's trades and holding each position for 1 Year would result in 79.17% of your transactions generating a profit, with an average return of +13.94% per trade.

2 Years

Stan BerenshteynWells Fargo

Success Rate

35/40 ratings generated profit

Average Return

+23.08%

Copying Stan Berenshteyn's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +23.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2HE Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2HE has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2HE average Analyst price target in the past 3 months is 97.79.

Each month's total comprises the sum of three months' worth of ratings.

2HE Financial Forecast

2HE Earnings Forecast

Next quarter’s earnings estimate for 2HE is €0.99 with a range of €0.95 to €1.01. The previous quarter’s EPS was €1.06. 2HE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2HE has Performed in-line its overall industry.

2HE Sales Forecast

Next quarter’s sales forecast for 2HE is €297.64M with a range of €294.66M to €299.57M. The previous quarter’s sales results were €301.08M. 2HE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2HE has Performed in-line its overall industry.

2HE Stock Forecast FAQ

What is DE:2HE’s average 12-month price target, according to analysts?

Based on analyst ratings, Healthequity’s 12-month average price target is 97.79.

What is DE:2HE’s upside potential, based on the analysts’ average price target?

Healthequity has 16.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Healthequity a Buy, Sell or Hold?

Healthequity has a consensus rating of Strong Buy, which is based on 9 buy ratings, 0 hold ratings and 1 sell ratings.

What is Healthequity’s share price target?

The average share price target for Healthequity is 97.79. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €107.23 ,and the lowest forecast is €75.49. The average share price target represents 16.42% Increase from the current price of €84.

What do analysts say about Healthequity?

Healthequity’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Healthequity?

To buy shares of DE:2HE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Healthequity (2HE) Stock Forecast & Price Target

2HE Analyst Ratings

2HE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Healthequity

2HE Analyst Recommendation Trends

2HE Financial Forecast

2HE Earnings Forecast

2HE Sales Forecast

2HE Stock Forecast FAQ

Detailed List of Analyst Forecasts